TMCnet News
CTD Holdings Announces Expanded Access Protocol using Intravenous Trappsol® Cyclo™ for Alzheimer's DiseaseProtocol Available on ClinicalTrials.gov ALACHUA, Fla., Aug. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the protocol for use of the company’s proprietary hydroxypropyl beta cyclodextrin, Trappsol(R) Cyclo(TM), in a single patient with late onset Alzheimer’s Disease is now publicly available on ClinicalTrials.gov (NCT 03624842). The Principal Investigator for the protocol is Diana Kerwin, M.D., President of Kerwin Research Center and a recognized expert in Alzheimer’s Disease and memory disorders. The Kerwin Research Center is sponsoring the project with CTD Holdings as collaborating partner. “With this cooperative research program, we will continue to advance our knowledge of how Trappsol(R) Cyclo(TM) interacts with cholesterol in patients with cholesterol-related disease. This knowledge will help us as we seek to develop therapies for Alzheimer’s Disease and other indications,” said N. Scott Fine, CTD’s Chairman and CEO. Cholesterol has been linked to the formation of amyloid beta plaques, one of the hallmarks of Alzheimer’s disease. Hydroxypropyl beta cyclodextrins have been shown to clear cholesterol from cells, to stabilize cholesterol metabolism, and to reduce the formation of amyloid beta plaques in animal models. CTD currently supports two clinical trials (NCT02939547 and NCT02912793) using Trappsol(R) Cyclo(TM) intravenously in patients with Niemann-Pick Disease Type C (NPC), a rare and fatal disease in which cholesterol accumulates in every cell in the body. NPC has also been called “Childhood Alzheimer’s” due to the cognitive decline which is apparent in many NPC patients. “I am pleased to be working with CTD on this program, and to build on the platform of safety data and knowledge within the company on cyclodextrins and their potential to addres cholesterol-related diseases. With millions suffering from Alzheimer’s Disease in the United States alone, this collaboration is very timely,” said Dr. Kerwin. The protocol describes an initial dosing regimen of 500 mg/kg given intravenously, with monthly increases in dose provided that safety and tolerability features are positive. “We will examine a number of factors to assess the risk-benefit ratio, including brain imaging, adverse events, changes in blood biomarkers, and pharmacokinetic data,” said Sharon Hrynkow, Ph.D., CTD’s Senior Vice President for Medical Affairs. “What we learn will be important not only to the single patient involved in this current project, but also potentially for all of CTD’s clinical studies, including our priority trials on Niemann-Pick Disease Type C.” About CTD Holdings: Safe Harbor Statement: Investor/Media Contact: Thomas Mulligan |